- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer | Clinical
Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14, 2022
During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Adjuvant Osimertinib Shows 77% Reduction in Disease Recurrence Risk in Early-Stage EGFR-Mutated NSCLC
September 11, 2022
Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.
Sintilimab Plus Chemotherapy Elicits PFS Benefit in EGFR-mutated Non-Squamous NSCLC
September 08, 2022
Findings from the phase 3 ORIENT-31 study shows improved progression-free survival with sintilimab with or without bevacizumab biosimilar injection and chemotherapy in EGFR-mutated non-squamous non-small cell lung-cancer.
Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion
September 07, 2022
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Approaching Treatment for a Patient With NSCLC and an EGFR Mutation
September 06, 2022
During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.
Abivertinib Shows Long-Term Efficacy in EGFR+ NSCLC With T790M Mutation
August 25, 2022
The novel targeted therapy abivertinib showed efficacy in a clinical trial of patients with EGFR T790M mutations who previously received an EGFR inhibitor.
Responses Shown With Amivantamab with lazeritinib and Chemo in EGFR+ NSCLC
August 13, 2022
Melina E. Marmarelis, MD, reports the safety and efficacy data from the phase 1 CHRYSALIS-2 trial.
EGFR C797X Becomes Leading Mechanism Following Osimertinib in NSCLC
August 08, 2022
Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.
Amivantamab Plus Lazertinib and Chemo Elicits Encouraging ORR in Pretreated EGFR-Mutant NSCLC
August 08, 2022
Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC
August 03, 2022
During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.